Search
Lenvatinib
go.drugbank.com/drugs/DB09078ApprovedInvestigationalfactor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. … In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamidePrimaquine
go.drugbank.com/drugs/DB01087ApprovedInvestigationalAn aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. … It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria.
Synonyms: 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline, 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinolineCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigationalMycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). … It demonstrates an increased bioavailability, a higher efficacy, and reduced gastrointestinal effects when compared to MPA.[A180826]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoateNabumetone
go.drugbank.com/drugs/DB00461Approved[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. … [A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.
Mixtures: NuDroxiPAK N-500Categories: COX-2 Inhibitors, Cytochrome P-450 SubstratesRosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalMore specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,[A181421] which catalyzes the conversion of HMG-CoA to mevalonic acid and is … found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.
Synonyms: (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acidMixtures: ZENIBE ® 10 MG + 40 MG TABLETAS RECUBIERTAS, LIPIVAN E ® 10 MG / 10 MGVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineEfavirenz
go.drugbank.com/drugs/DB00625ApprovedInvestigationalEfavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human … a high risk for HIV transmission.
Mixtures: Efatriten 600 mg/200 mg/245 mg Filmtabletten, Padviram 600 mg/200 mg/245 mg - FilmtablettenCategories: Antivirals used in combination for the treatment of HIV infections, P-glycoprotein substratesCiprofloxacin
go.drugbank.com/drugs/DB00537ApprovedInvestigationalCiprofloxacin is a second generation fluoroquinolone that has spawned many derivative antibiotics. … [A178870] It is formulated for oral, intravenous, intratympanic, ophthalmic, and otic administration for a number of bacterial infections.
Mixtures: InfectoCiproCort 3 mg/ml + 0,25 mg/ml Ohrentropfen, Lösung, OTOFAST®Categories: 4-Quinolones, MATE 1 InhibitorsDelamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalIt is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. … In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background
Synonyms: (2R)-2-methyl-6-nitro-2-((4-(4-(4-(trifluoromethoxy)phenoxy)piperidin-1-yl)phenoxy)methyl)-2,3-dihydroimidazo(2,1-B)(1,3)oxazole, (R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazoleCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesMycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis.
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid